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Abstract.  Circumsporozoite (CS) proteins, which 
densely coat malaria (Plasmodia) sporozoites, contain 
an amino acid sequence that is homologous to seg- 
ments in other proteins which bind specifically to sul- 
fated glycoconjugates. The presence of this homology 
suggests that sporozoites and CS proteins may also 
bind sulfated glycoconjugates. To test this hypothesis, 
recombinant P. yoelii CS protein was examined for 
binding to sulfated glycoconjugate-Sepharoses. CS 
protein bound avidly to heparin-, fucoidan-, and dex- 
tran sulfate-Sepharose, but bound comparatively 
poorly to chondroitin sulfate A- or C-Sepharose. CS 
protein also bound with significantly lower affinity to 
a heparan sulfate biosynthesis-deficient mutant cell 
line compared with the wild-type line, consistent with 
the possibility that the protein also binds to sulfated 
glycoconjugates on the surfaces of cells. This possibil- 
ity is consistent with the observation that CS protein 
binding to hepatocytes, cells invaded by sporozoites 
during the primary stage of malaria infection, was in- 
hibited by fucoidan, pentosan polysulfate, and heparin. 
The effects of sulfated glycoconjugates on sporozoite 
infectivity were also determined. P. berghei 
sporozoites bound specifically to sulfatide (galac- 
tosyl[3-sulfate]/~l-lceramide), but not to comparable 
levels of cholesterol-3-sulfate, or several examples of 
neutral glycosphingolipids, gangliosides, or phospho- 
lipids.  Sporozoite invasion into hepatocytes was in- 
hibited by fucoidan, heparin, and dextran sulfate, 
paralleling the observed binding of CS protein to the 
corresponding Sepharose derivatives. These sulfated 
glycoconjugates blocked invasion by inhibiting an 
event occurring within 3 h of combining sporozoites 
and hepatocytes. Sporozoite infectivity in mice was 
significantly inhibited by dextran sulfate 500,000 and 
fucoidan. Taken together, these data indicate that CS 
proteins bind selectively to certain sulfated glycocon- 
jugates, that sporozoite infectivity can be inhibited by 
such compounds, and that invasion of host hepatocytes 
by sporozoites may involve interactions with these 
types of compounds. 
T 
o initiate an infection, malaria (Plasmodium sp.) spor- 
ozoites must pass  from the salivary gland of an in- 
fected 'Anopheles mosquito  into  the  host's  blood 
stream during feeding, followed by invasion of host hepato- 
cytes. Little is known of  the mechanisms used by sporozoites 
to arrive at their desired destination and then to selectively 
bind  to  and  invade  host  hepatocytes.  Circumsporozoite 
(CS) ~  proteins densely coat sporozoites,  and these proteins 
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1. Abbreviation  used in this paper: CS, circumsporozoite. 
apparently play a critical role in the invasion of sporozoites 
into hepatocytes since some antibodies against such proteins 
inhibit invasion of hepatocytes and the cell surface expres- 
sion of CS proteins correlates with sporozoite infectivity (for 
review see reference 13). The sequences of all CS proteins 
reported to date contain the amino acid homology Cys-Ser- 
Val-Thr-Cys-Gly-x-Gly-x-x-x-Arg-x-Arg/Lys (see references 
in 7). Thus, this sequence, located in the carboxyl-terminal 
of the protein referred to as region II, may encode a crucial 
CS protein functional domain.  This amino acid homology 
also occurs in the recently described sporozoite surface pro- 
tein 2 (6), a minor component of the cell surface proteins on 
sporozoites, further suggesting that this domain plays an im- 
portant role for the malaria parasite. 
Interestingly,  thrombospondin,  von  Willebrand  factor, 
collagen Type IV, ~2 glycoprotein I, antistasin, and proper- 
din also possess one or more examples of the amino acid ho- 
mology sequence described above (7). Although these pro- 
teins  are involved in widely diverse biological  processes, 
they all specifically bind sulfated glycoconjugates (8). For 
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observed to bind with comparatively high affinity to sulfated 
glycoconjugates such as heparin, fucoidan, and dextran sul- 
fates, but only weakly to chondroitin sulfates (7, 8, and refer- 
ences therein).  Therefore, it has been hypothesized that the 
amino acid homology segment may be a sulfated glycocon- 
jugate-binding domain (8). 
The potential of malaria sporozoites and CS proteins to 
specifically  interact with sulfated glycoconjugates is exam- 
ined in this report. First, we investigated CS protein binding 
to  sulfated  glycoconjugate-Sepharoses.  We also examined 
CS protein binding to heparan sulfate biosynthesis-deficient 
mutant and wild-type CHO calls, as well as to murine hepa- 
tocytes. The effects of sulfated glycoconjugates on infectious 
sporozoites  were  also  investigated.  Sporozoite  binding  to 
surfaces coated with various glycolipids and other test com- 
pounds  was  determined.  A  battery  of sulfated  glycocon- 
jugates was evaluated for their potency to inhibit the infec- 
tion  of  hepatocytes  by  sporozoites,  and  the  kinetics  of 
inhibition  is  examined.  Finally,  the  ability  of  sulfated 
glycoconjugates to inhibit malaria spomzoite infectivity  in 
vivo was evaluated. 
Materials and Methods 
Materials 
Glycosphingolipids  were purchased from Sigma Chem. Co. (St.  Louis, 
MO), Sup~  Inc.  (Bell~176  PA), or  Bachem California  (Torrance,  CA). 
Hcparin-Sepharose was from  Pbarmacia LKB Biotechnology Inc.  (Piscata- 
way,  NJ).  Hcparin,  hyaluronic  acid,  and  chondroitin  sulfates  A and  C were 
from Caibiochem-Behring Corp., San Diego, CA. Fatty  acid-free  BSA, 
phospbolipids,  pentosan polysulfate,  chondroitin  sulfate  13,  cholesterol-3- 
sulfate, dextran sulfates 5,000 and 500,000, and fucoidan were from Sigma 
Chem. Co. Human thrombospondin  was purified as described (7). Immuno- 
afffinity-purified, full-length recombinant P. yoelii CS protein, expressed in 
Salmonella typhimurium (21), was produced by Drs. W. Weiss and L. Yuan 
(Naval Medical Research Institute, Bethesda, MD) from transformed Sal- 
monella typhimurium provided by Dr. A. Aggarwal (Walter Reed Army In- 
stitute of  Research,  Washington, DC). ANKA  clone  P. berghei  sporozoites 
were prepared from infected  Anopheles stephensii  mosquitoes using the 
method of  Mellouk et ai. (12). 
Preparation of  Modified Sepharoses 
Sulfated  glycoconjugates  were  coupled  to  dlvinylsulfone-activated 
Sepharose 6B by the method of Porath (15). The amounts of glycoconjugate 
coupled to Sepbarose, determined by phenol/sulfuric acid assays (17), were 
as follows: fucoidan,  0.87 mg/mi; dextran sulfate 5,000, 2.09 mg/mi; dex- 
tran sulfate 500,000,  1.81 m~/ml; cbondroitin sulfate A, 1.74 mg/ml; chow 
droitin sulfate C, 0.93 mg/rhl. 
CS Protein Binding Assays to Modified Sepharoses 
CS protein or thrombospondin were radiolabeled with n5I (ICN Biomedi- 
cais, Inc., Costa Mesa, CA) as described (19), except that unincorporated 
t25I was  removed  on columns of Bio-Gel Pl0 (100-200 mesh, Bio-Rad 
Labs.-Chem.  Div.,  Richmond, CA).  The following  manipulations were 
done at room temperature.  Triplicate columns of modified Sepharose (150 
~d) were preblocked by washing extensively with 50 ~  Tris, pH 7.8, 120 
mM NaC1, 2.5 mM CaCI2, 1% BSA. The columns were next equilibrated 
in 50 mM "I~is, pH 7.8, 2.5 mM CaCI2 (buffer A) and 125I-proteins  (40-800 
fmol)  were applied in buffer A  containing 30 mM NaCI,  0.25%  BSA. 
Columns contained at least 100-fold molar excess of derivatized  sulfated 
glycoconjugates  compared  with  the  radiolabeled  samples  added.  The 
columns were washed with buffer A (3  ￿  1 ml), and then ~  succes- 
sively with I ml each of buffer A containing 0.15, 0.3, 0.45, or 0.6 M NaC1. 
Radiolabeled  material ~  in each fraction was determined by V-count- 
ing.  ~2sI-Proteins ~  in buffer A containing 0.15-M NaC1 concentra- 
tions or higher were included in calculations of the protein bound to a given 
column.  Calculations of moles bound were made by first correcting for 
binding to unmodified Sepharose, which was 11 and 13% of maximal bind- 
ing observed to modified  Sepbaroses  for t25I-thmmbospondin  and 125I-CS 
protein,  respectively.  Thrombospondin had been affinity  purified on a 
heparin-Sepharose column before iodination (7). Iodinatiun  produced a ma- 
jor loss of heparin binding activity, resulting in only ,,o20% of t25I-throm- 
bospondin binding to heparin-Sepharose.  The extent of loss of CS protein 
binding activity after iodination is unknown since this cloned gene product 
was  of uncertain conformationai state and,  although it had been im- 
munoaffnity purified  before labeling, had not been affinity  purified on 
heparin-Sepharose. 
CS Protein Binding to Cells 
Wild-type (K1) or heparan sulfate biosynthesis-deficient  (pgsA 803, ,~90 % 
reduced heparan sulfate and "~  reduced chondroitin sulfate biosynthe- 
sis) CHO  cell lines (5)  were generously provided by Dr.  Jeffrey  Esko 
(University of Alabama at Birmingham). Trypsinized  cells (400 pl, 2  ￿ 
105 cells/mi in Ham's FI2 media, 5% FCS,  100 U/ml penicillin, 100 gg/ml 
streptomycin)  were  aiiquoted  in the  wells  of Cluster  u  plates  (Costar 
Corp., Cambridge,  MA). The cells were cultured 18 h at 37~  in a 5% 
CO2  atmosphere,  reconstituting  their  surfaces  and  achieving  ~70% 
confluence.  The wells were gently washed three times with ice-cold buffer 
A containing 1% BSA, 0.15 M NaC1. Dilutions of 125I-pmteins in the same 
buffer were aliquoted into duplicate wells (El pmol/well at highest concen- 
tration; diluted 1:2 thereafter), and the plates were incubated 3 h at 4~ 
Unbound material was removed from the plate with five washes of ice-cold 
PBS, and the bound 125I-proteins were quantitated by "y-counting and cor- 
rected for binding to wells without cells. Microscopic inspection  and trypan 
blue dye exclusion of wells treated in parallel indicated that cell viability 
remained >90% in these experiments. 
For assays of the inhibitory potency of sulfated glycoconjugates  on CS 
protein  binding  to  hepatocytes,  hepatocytes  were  prepared  from 
collagenase-treated  BALB/c mouse livers as described (12). Hepatocytes 
were aiiquoted into the wells of Cluster  u  plates (1 mi, 2  x  105 cells/rnl in 
MEM supplemented as described in reference  12), and incubated 18 h at 
37~  in a 5% CO2 atmosphere, which gave ,,070% confluence.  The wells 
were gently washed three times with ice-cold buffer A containing 1% BSA, 
0.15 M  NaC1. Triplicate samples  of nSI-proteins  (~2.0 pmul in 250 ~l) 
containing inhibitors at 400 gg/mi in the same buffer were aliquoted into 
wells, and the plates incubated 2 h at 4~  Unbound material was removed 
from the plate with four washes of ice-cold buffer A containing 1% BSA, 
0.15 M NaCI.  Bound mI-proteins were quantitated by V-counting. Inhibi- 
tors had no effect on cell viability,  as judged by the lack of an apparent 
change in cell confluence in their presence. 
Sporozoite Binding on Lipid-coated Glass Slides 
Test materials were diluted in phospbatidylcholine and cholesterol (200 
ng/ml each in methanol). 5-~d aliquots were air dried in the wells of HTC 
(heavy teflon coated)  supercured glass slides (Cel-Line Assoc.,  Newfield, 
NJ), and the slides were blocked by incubation in buffer A containing 1% 
BSA, 0.15 M NaC1 for 18 h at 370C. The blocked slides were rinsed with 
distilled water and air dried. Freshly isolated sporozoites  (10 ~tl, 3  ￿  105 
per ml in  RPMI-1640, 5% FCS, I0 mM  Hepes, pH 7.4)  were overlaid  in 
the slide wells, and binding proceeded 3 h at 4~  Excess cells were washed 
from the slides with PBS. Sporozoite binding was determined blindly by im- 
munofluorescence  microscopy  with anti-P, berghei CS protein repeat re- 
glen mAb, NBS1 (kindly provided by Dr. Y. Charoenvit, Naval Medical Re- 
search Institute, Bethesda, MD) and fluoresceinated  rabbit anti-mouse IgG 
antisera (Miles-Yeda Inc., Elkhart, IN). 
Sporozoite Infection Assays with Hepatocytes 
Hepatocytes were prepared as above, and 105 cells were plated in chamber 
slide plates (Lab-Tek Div. Miles Laboratories Inc., Naperville, IL) over- 
night. Freshly isolated  sporozoites  (12) and inhibitor were combined in 
RPMI-1640, containing 5 % FCS and 10 mM Hepes, and 75 ~tl (2--4 x  104 
spomzoites)  was added to triplicate wells.  After an incubation of 3 h at 
37~  unbound spomzoites  were gently rinsed from the plates with sup- 
plemented MEM. The plates were incubated for an additional 45 h, replac- 
ing the media at 24 h, and then fixed and stained for schizonts using an in- 
direct fluorescent antibody test (12). To determine if the inhibitory activity 
of sulfated  glycoconjngates  required their interaction with extracellular 
sporozoites,  inhibitors were added to hepatocytes for 3 h before sporozoite 
addition and then rinsed away, or for 3 h with sporozoites,  or for 21 h after 
the 3-h incubation with sporozoites. It should be noted that sporozoites typi- 
cally complete invasion of hepatocytes  with 3 h of incubation together.  In 
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compared with uninhibited (PBS) controls. Uninhibited controls averaged 
513  schizonts/well over eight independent experiments,  with deviations 
within triplicates (an-l) averaging 9.7 % of the number of schizonts detected 
in each experiment. Inhibitors had no effect on hepatocyte viability, as 
judged by a lack of detectable change in general morphology or substrate 
attachment. Inhibitors also had no apparent effect on sporozoite viability, 
judged by no detectable changes in the parasite's morphology, trypan blue 
dye exclusion, or motility. 
Sporozoite Infection Assays with Mice 
Sporozoites were combined with inhibitor (1 mg/ml) for 15 rain at O~  The 
mixtures (0.1 mi, containing 800-2,000 sporozoites, depending on the trial) 
were  injected  into  the  tail  veins  of "r  female  BALB/c  mice. 
Giemsa-stained blood smears were examined for parasites for 21 d, or until 
the animal became positive for parasitemia. 
Results 
CS Protein Binding to 
Sulfated Glycoconjugate-Sepharoses 
The possibility that CS proteins bind specifically to sulfated 
glycoconjugates, suggested by the occurrence of a putative 
sulfated  glycoconjugate-binding  domain  in  the  protein's 
sequence,  was  examined  by  several  approaches.  In  one, 
recombinant P. yoelii CS protein binding to sulfated glyco- 
conjugate-Sepharoses  was  determined.  The  CS  protein 
bound extensively to dextran sulfate 500,000- and heparin- 
Sepharose, and to a lesser extent to fucoidan- and dextran 
sulfate 5,000-Sepharose (Fig. 1). The binding of the CS pro- 
tein to chondroitin sulfate A- or C-Sepharose was low; only 
slightly more CS protein bound to these resins than to un- 
modified Sepharose. Since the charge densities of chondroi- 
tin sulfates A and C are similar to fucoidan, heparin, and 
dextran sulfates (2), the differences observed in CS protein 
binding  to  the  sulfated glycoconjugate-Sepharoses is  not 
simply the result of nonspecific charge interactions. 
Human thrombospondin, which contains three copies of 
the homology sequence described above,  has been exten- 
sively characterized  as  a  sulfated glycoconjugate-binding 
protein  (see  references  7,  8,  19,  and  references  therein). 
Therefore, the binding pattern of thrombospondin on the sul- 
fated glycoconjugate-Sepharoses was determined for com- 
parison with the pattern observed for CS protein. The order 
of binding preferences for thrombospondin to the modified 
Sepharoses was remarkably similar to that of the CS protein 
and the selectivity of binding of CS protein to the dextran 
sulfates, fucoidan, and heparin vs.  the chondroitin sulfates 
was as good or better than that observed for thrombospondin 
(Fig.  1). It should also be noted that CS protein and throm- 
bospondin both bind to the modified Sepharoses with orders 
of preference similar to the sulfated glycoconjugate-binding 
affinities  reported  for  antistasin  and  properdin,  both  of 
which also contain the homology sequence described above 
(8).  This binding is clearly different from that of such com- 
pounds as BSA, which was present in large excess during the 
binding of CS protein and thrombospondin. Also, binding of 
iodinated BSA to columns of derivatized Sepharoses under 
these conditions was <0.2 mol/mol CS protein bound. 
CS Protein Binding to Cell Surfaces 
CS  protein  was  also  examined  for  binding  to  sulfated 
glycoconjugates in the less artificial context of cell surfaces. 
Figure 1. CS protein and thrombospondin bind specifically  to sul- 
fated glycoconjugate-Sepharose. 125I-CS protein or t2sI-thrombo- 
spondin was passed over columns of modified  Sepharose  and eluted 
as described in Materials and Methods. 125I-Protein binding to 
modified Sepharoses corrected for binding to unmodified Seph- 
arose is shown. Data are normalized to binding per pmol thrombo- 
spondin of CS protein added. Dex Sulf5OOk and Dex Sulf5k, dex- 
tran sulfate 500,000 and 5,000, respectively; Chond Sulf A and 
Chond Sulf C, chondroitin sulfates A and C, respectively. Error 
bars represent SD (on-l). 
Recently, a cell line (pgsA 803) with a mutation in heparan 
sulfate biosynthesis, resulting in a 90% reduction of cell sur- 
face heparan sulfates relative to the parental (K1) line, was 
described by Esko et al.  (4).  As shown in Fig. 2,  throm- 
bospondin  binding  to  the  heparan  sulfate  biosynthesis- 
deficient cells was  greatly diminished compared with the 
binding to wild-type cells. These observations are consistent 
with previous reports  suggesting that thrombospondin can 
interact with the surfaces of various cell types via sulfated 
glycoconjugates such as heparan sulfate (for review see ref- 
erence  5).  CS  protein  binding  to  the  heparan  sulfate 
biosynthesis-deficient cells was also greatly reduced com- 
pared with that seen to the wild-type cells (Fig. 2), suggest- 
ing that this protein can also bind cell surface heparan sul- 
fates. 
The  potency of sulfated glycoconjugates to  inhibit the 
binding of CS protein to the surfaces of murine hepatocytes, 
cells  invaded by  sporozoites during the primary  stage of 
malaria infection, was also determined. CS protein binding 
to hepatocytes was inhibited by fucoidan, heparin, and pen- 
tosan polysulfate (Fig. 3). The activity of fucoidan and hepa- 
rin is consistent with the binding preferences of CS protein 
observed for the corresponding modified Sepharoses (Fig. 
1). Dextran sulfate 500,000 and the chondroitin sulfates all 
showed similar,  moderate levels  of inhibitory activity, in 
contrast to  binding to  their  Sepharose  derivatives, while 
hyaluronic acid demonstrated none. Thrombospondin bind- 
ing to hepatocytes was best inhibited by heparin and pento- 
san polysulfate, moderately by the chondroitin sulfates, and 
not at all by dextran sulfate 500,000 or fucoidan, This pattern 
of inhibitory activity clearly differed from the binding activi- 
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Figure 2.  A mutation in the biosynthesis of heparan sulfate de- 
creases the binding of CS protein to cell surfaces. 12~I-CS protein 
or 12sI-thrombospondin was incubated with heparan  sulfate bio- 
synthesis-deficient  mutant (803) or wild-type (K/) cell lines adher- 
ing to the bottoms of microtiter wells. After an incubation of 3 h 
at 4~  the wells were washed and the bound protein was quan- 
titated.  Data  are expressed as  fmoles  usI-CS protein  (CS), or 
~2hhrombospondin bound (y axis) vs.  fmol added (x axis).  The 
average of the SD (o,-i) for these data  is 5.5% of the average 
moles bound. 
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Figure 4. Sporozoites bind specifically to sulfatide. Live P. berghei 
sporozoites  were  overlaid on glass slides  coated  with  varying 
amounts of  the indicated material. After an incubation of  3 h at 4~ 
excess cells were removed and bound cells were quantitated by 
immunofluorescence microscopy. (o) Sulfatide; (o) cholesterol- 
3-sulfate; (A) GMl; (/9 phosphatidylserine;  (I) galactosylcera- 
mide; (---) phosphatidylcholine/cholesterol. Error bars represent 
SD (a,-0. 
ties observed for the corresponding Sepharose derivatives. 
One explanation for this observation is that thrombospondin 
has at least one other sulfated glycoconjugate-binding do- 
main distinct from the one encoded by the amino acid homol- 
ogy sequence described above, presumably with a somewhat 
different specificity, as well as two additional types of bind- 
Figure 3. Inhibition of  CS protein binding to hepatocytes by sulfated 
glycoconjugates, t2~I-CS protein or 125I-thrombospondin  were in- 
cubated in the presence of the indicated inhibitors with murine he- 
patocytes adhering to the bottoms of microtiter wells. After an in- 
cubation of  2 h at 4"C, the wells were washed and the bound protein 
was quantitated. Percent inhibitions are calculated relative to the 
binding observed for controls in which no inhibitor was added. 
Dex. sulfate 50Ok, Pentosan, Chond. sulfate A, and Chond. sulfate 
C, dextran sulfate 500,000, pentosan polysulfate, chondroitin sul- 
fate A, and chondroitin sulfate C, respectively. 
ing sites, an RGD binding site and a platelet/cell binding site 
(for review see reference 16).  That neither CS protein nor 
thrombospondin binding is inhibited by hyaluronic acid,  a 
highly  carboxylated, high molecular weight carbohydrate 
polymer that does not contain sulfate moieties, as well as the 
wide range of inhibitory activities demonstrated by the vari- 
ous  sulfate  containing  glycoconjugates,  suggests  that  the 
binding of these proteins to hepatocytes is not primarily the 
result of nonspecific charge effects. 
Sporozoite Binding to Glycolipid-coated  Surfaces 
CS  proteins  densely  coat  the  surfaces  of  Plasmodium 
sporozoites (13). Therefore, it was suggested by the CS pro- 
tein binding data presented above that sporozoites may also 
bind specifically to sulfated glycoconjugates. In one set of 
experiments designed to evaluate this possibility, P. berghei 
sporozoites were examined for binding to test materials im- 
mobilized on glass slides. As shown in Fig. 4,  sporozoites 
bind in comparatively high numbers to slides coated with the 
sulfated glycolipid, sulfatide (galactosyl [3-sulfate]~-lcer- 
amide).  In contrast,  sporozoites bind at,  or below, back- 
ground  levels  to  slides  coated with  cholesterol-3-sulfate, 
phosphatidylserine, GM ~, or GM2 (Fig. 4;  GM2,  data not 
shown),  suggesting  that  sporozoites  binding  to  sulfatide 
is  not due to nonspecific charge interactions.  Sporozoites 
also do not bind selectively to galactosylceramide (Gal~l- 
lceramide)-coated surfaces, indicating that a sulfate moiety 
must be present on the glycoconjugate portion of this glyco- 
lipid for binding. 
Inhibition of  Sporozoite Infection of  Hepatocytes by 
Sulfated Glycoconjugates 
Sulfated glycoconjugates were assayed for their relative abil- 
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by Sulfated Glycoconjugates* 
Inhibition (%)r 
Inhibitorsw  Trial  1  Trial 2  Trial 3 
Dextran  sulfate 500,000 
400/~g/ml  -  89  - 
Dextran  sulfate 5,000 
1,000  ~g/ml  94  -  - 
400/~g/ml  -  78  63 
Fucoidan 
1,000/zg/ml  86  -  - 
400 ~g/ml  -  54  58 
Heparin 
1,000  #g/ml  53  -  - 
400/zg/ml  -  72  70 
Chondroitin  sulfate A 
2,000/zg/ml  -  -  6 
400/zg/ml  -  9  0 
Chondroitin  sulfate B 
400/zg/ml  -  0  - 
Chondroitin  sulfate C 
2,000  ~g/ml  -  -  22 
400 #g/ml  -  25  5 
Hyaluronic acid 
400/zg/ml  -  20  - 
* Sporozoites were overlaid 3 h on hepatocytes bound to slides, the slides were 
rinsed, and schizonts developing after 48 h  were counted. 
~: Inhibition relative to PBS  added alone.  The  total number of schizonts de- 
veloping in triplicate wells in the presence of PBS alone were 906, 2,751, and 
1,883  for trials 1,  2,  and 3,  respectively. 
w Inhibitors were present only during the initial 3-h incubation. 
ities to inhibit the infection of mouse hepatocytes by P. ber- 
ghei sporozoites.  P.  berghei sporozoites were used rather 
than P. yoelii sporozoites because of their greater infectivity 
for mouse hepatocytes in vitro. In addition, P. berghei and 
P. yoelii CS proteins differ at only 2 amino acids out of 16 
in  the  region of homology (consensus  region)  described 
above (20).  Dextran sulfates 5,000 and 500,000,  fucoidan, 
and heparin were found to be good inhibitors of hepatocyte 
infection (Table I), consistent with the CS protein binding in- 
hibition assays shown in Fig. 3. In contrast, hyaluronic acid, 
and chondroitin sulfates A, B, and C added at the same con- 
centrations produced limited or probably no inhibition of  he- 
patocyte infection since adding fivefold higher concentra- 
tions of chondroitin sulfate A or C had little effect. Thus, 
these data indicate that certain sulfated glycoconjugate struc- 
tures clearly effectively  inhibit sporozoite invasion of  hepato- 
cytes while others give little or no inhibition. 
The time course for the inhibition of hepatocyte infection 
by sulfated glycoconjugates was also examined (Table II). 
Addition of dextran sulfate 5,000  to the hepatocyte culture 
media for 3 h, rinsing the inhibitor away, and then adding 
sporozoites produced little or no decrease in the number of 
cells infected. Similarly, combining sporozoites and hepato- 
cytes for 3 h, rinsing unbound sporozoites away, and then 
adding inhibitor to the culture media for 21 h had no effects 
on the number of  infected cells. A major reduction in hepato- 
cyte infection was only observed when inhibitor was added 
at the same time as sporozoites. Therefore, these data sug- 
gest that sulfated glycoconjugates inhibit sporozoite infec- 
Table II. Time Course of  lnhibition of Sporozoite Infectivity 
in Hepatocytes by Dextran Sulfate 5,000" 
Inhibition~  t 
Time inhibitor addedw  Experiment 1  Experiment 2  Experiment 3 
%  %  % 
-3  to0h 
2  mg/ml  -  26  +  5  - 
1  mg/ml  2  5:11  -  - 
0to3h 
1 mg/ml  58  +  6  73  +  9  97  +  3 
0.2  mg/ml  -  -  91  +  3 
3  to24h 
1  mg/ml  -  0  +  11  - 
0.2  mg/ml  -  -  0.24 
* Sporozoites were overlaid 3 h on hepatocytes bound to slides, the slides were 
rinsed, and schizonts developing after 48 h  counted. 
~: Inhibition relative to PBS added alone. 
w 0  h  refers  to  the  time  when  sporozoites  were  first  overlaid  on  the 
hepatocytes. 
tivity by a mechanism that requires contact between these in- 
hibitors and extracellular  sporozoites. 
Inhibition of Sporozoite Infection of  Mice by 
Sulfated Glycoconjugates 
The possibility that sulfated glycoconjugates are inhibitory 
to sporozoite infectivity in in vivo assays, as they are in the 
in vitro assays presented above, was also investigated. Mice 
were injected with sporozoites in combination with various 
inhibitors,  and  the  mice  were  examined  for  parasitemia. 
Fucoidan  and  dextran  sulfate  500,000  clearly  inhibited 
sporozoite infectivity in vivo (Table III), paralleling the ob- 
servation that these compounds were also among the most 
effective reagents tested in blocking the in vitro invasion of 
hepatocytes by sporozoites (Table I).  Heparin,  dextran sul- 
fate 5,000, chondroitin sulfate C, and hyaluronic acid did not 
clearly inhibit the ability of sporozoites to infect mice, indi- 
cating a highly selective pattern for in vivo inhibitory activ- 
ity and that the inhibitory effects of fucoidan and dextran sul- 
fate 500,000 are not the result of nonspecific charge effects. 
Table IlL Inhibition of  Sporozoite Infectivity in Mice 
by Sulfated Glycoconjugates* 
Inhibitor  Infected~:  Trials  Mice (total)w 
% 
Dextran  sulfate 500,000  44  +  10  3  18 
Dextran  sulfate 5,000  100  :i:  0  2  12 
Fucoidan  17  -t-  14  4  24 
Heparin  81  +  25  6  34 
Chondroitin  sulfate C  83  +  29  3  18 
Hyaluronic acid  100  +  0  3  18 
PBS  94  +  14  6  34 
* Sporozoites were combined with inhibitor (1 mg/ml) for 15 min, and 0,1 rrd 
was injected i.e. per mouse. Blood smears were examined for 21 d, or until 
the animal became parasitemic. 
~: Mean infected +  a~_~ for the trials was calculated by averaging the number 
of mice infected per mice injected in each trial. 
w Between 5  and 7  mice were injected with the test inhibitors in each trial. 
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The mechanisms by which Plasmodium sp.  sporozoites lo- 
cate, bind to, and invade hepatocytes are not known but un- 
doubtedly involve a number of processes, which in molecu- 
lar terms must be highly complex. CS protein is thought to 
play a critical role in mediating the invasion process since 
(a) CS proteins densely coat sporozoites; (b) the cell surface 
expression  of  CS  proteins  is  thought  to  correlate  with 
sporozoite infectivity (for reviews see reference 13); and (c) 
antibodies against CS proteins can inhibit invasion (1, and 
references therein). Several recent reports have pursued a de- 
termination of how CS protein may function on the surface 
of sporozoites. Robson et al. (20) have noted that CS protein, 
as well as a malaria blood-stage protein, thrombospondin- 
related anonymous protein, contain amino acid sequences 
that are homologous to sequences in thrombospondin and 
properdin. Holt et al. (7) found that a portion of this homol- 
ogy, based on the sequence Cys-Ser-Val-Thr-Cys-Gly-x-Gly- 
x-x-x-Arg-x-Arg/Lys, occurs in several proteins which bind 
specifically to sulfated glycoconjugates. Therefore, it was 
proposed that this sequence may constitute a sulfated glyco- 
conjugate-binding domain. This possibility was supported 
by research indicating that several otherwise-unrelated pro- 
teins which contain the homology sequence have remarkably 
similar sulfated glycoconjugate-binding characteristics (8). 
In this report we have investigated the hypothesis that CS 
protein binds  selectively to  sulfated glycoconjugates and 
have tested the effects of these compounds on sporozoite in- 
fectivity. We have shown that a recombinant P. yoelii CS pro- 
tein binds avidly to heparin-,  fucoidan-, and dextran sul- 
fate-Sepharose,  but  binds  poorly  to  chondroitin  sulfate 
A- or C-Sepharose. The CS protein binds less extensively 
to a heparan sulfate biosynthesis-deficient  mutant compared 
with wild-type cells, and binding to hepatocytes is inhibited 
by fucoidan, pentosan polysulfate, and heparin, less so by 
dextran sulfate 500,000 and the chondroitin sulfates, and not 
at all by hyaluronic acid. Sporozoite invasion of hepatocytes 
is well inhibited by fucoidan, heparin, and the dextran sul- 
fates, and little or not at all by the chondroitin sulfates and 
hyaluronic acid. Furthermore, we have determined that sul- 
fated glycoconjugates inhibit an event of sporozoite invasion 
into hepatocytes which occurs within 3 h of combining the 
ceils. Finally, we show that sporozoite infectivity in mice is 
also substantially inhibited by fucoidan and high molecular 
weight dextran sulfate. 
Overall, our observations indicate that CS protein binds 
to  selected sulfated glycoconjugates and that these  same 
compounds  have  a  major  effect on  in  vitro  P.  berghei 
sporozoite infectivity. A subset of this same group of com- 
pounds clearly inhibits in vivo infectivity as well. The mo- 
lecular basis for these different observations and their possi- 
ble similar or dissimilar mechanistic basis with respect to the 
effects of sulfated glycoconjugates  remains to be determined. 
However, our observations are generally consistent with the 
possibility that interactions of sporozoites with hepatocyte 
cell surface sulfated glycoconjugates represent a step in the 
invasion process. Inhibition of sporozoite infectivity by sul- 
fated glycoconjugates  could then result from their competing 
with target cell sites for sporozoite surface ligands. This pos- 
sibility is supported by our observed selective binding of P. 
berghei sporozoites to sulfatide and the greatly reduced bind- 
ing of CS  protein to a  CHO cell mutant having reduced 
production of sulfated glycoconjugates, especially of bepa- 
ran sulfate, the primary sulfated glycoconjugate of hepato- 
cyte surfaces (11, 22, 23).  Published results indicating that 
invasion by Plasmodium sp.  sporozoites is associated with 
binding  of sporozoite  components  to  hepatocyte protein 
components (24)  are not necessarily inconsistent with the 
possible  interaction  of sporozoite  components,  even  the 
same components, with target cell sulfated glycoconjugates. 
For example, the uptake of fibroblast growth factor by target 
cells is known to be a  two-stage process,  a required low- 
affinity interaction with cell surface heparan sulfate followed 
by high-affinity binding to a specific protein receptor in the 
cell membrane (for review see reference 9). 
In  considering  that  CS  proteins  may bind  to  sulfated 
glycoconjugates via the described homology sequence,  it 
may be noted that the cell adhesive properties of selected 
peptides and protein fragments containing such a sequence 
have been previously demonstrated in other systems. Prater 
et al. (16) have shown that peptides which include the homol- 
ogy  sequence  occurring  in  thrombospondin  are  strongly 
adhesive for melanoma cells, and that cell binding to these 
peptides can be selectively inhibited by the sulfated glyco- 
conjugates, heparin, fucoidan, and dextran sulfate, the same 
compounds showing greatest activity in our studies. Hema- 
topoietic cell lines have been observed to adhere specifically 
to surfaces coated with synthetic peptides based on a portion 
of the homology sequence occurring in CS protein, includ- 
ing ones as small as Val-Thr-Cys-Gly  (18). What on the sur- 
faces of the hematopoietic cells is bound by, or binds to, 
these peptides has not been determined. Selective binding of 
sulfated glycoconjugates  to proteins not having such a region 
of sequence homology or by binding to sequentially unre- 
lated regions, as is seen for the heparin binding site initially 
described on thrombospondin (16), has also been observed 
in several studies, indicating that protein-sulfated glycocon- 
jugate interactions may involve other types of mechanisms 
as well. 
A  consideration in the hypothesis that CS proteins and 
sporozoites interact with sulfated glycoconjugates is  how 
specificity might enter into such an interaction. In this re- 
port, we have shown that CS protein, like several other pro- 
teins  described  in  the  past  (5,  7,  8,  19,  and  references 
therein),  binds  strongly  to  the  sulfated glycoconjugates, 
beparin and fucoidan, but only weakly to chondroitin sulfate 
A or C. Based on work in other systems, it is possible that 
CS proteins bind to only specific structures within a class of 
sulfated glycoconjugates and each class can show enormous 
structural diversity. For example, heparan sulfates can theo- 
retically occur as 103~ different structures (3). However, an- 
tithrombin HI only binds to specific pentasaccharides out of 
the enormous diversity of possible heparin structures (14). 
Furthermore, sulfated glycoconjugates are known to be both 
species and tissue specific.  For example, heparan sulfates 
isolated from rat liver differ significantly in size and fine 
structure (sulfation, acetylation, and branch positions) from 
those in rat kidney or human liver (3,  10,  11, 23). 
In considering the mechanisms by which selected sulfated 
glycoconjugates may inhibit sporozoite infectivity it should 
also be noted that sporozoites are now known to contain at 
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similar region of sequence homology, the sporozoite surface 
protein 2 of P. yoelii sporozoites  (6). 
It is of interest that the inoculation of P. berghei sporozo- 
ites with low levels  of dextran sulfate 500,000 or fucoidan 
can prevent infection of mice and that this is consistent with 
the effects of  these same compounds on sporozoite infectivity 
in in vitro assays. Although it is unclear why heparin and 
dextran sulfate  5,000,  which has  a  similar  structure and 
charge density as dextran sulfate 500,000,  inhibit in vitro but 
not in vivo infectivity,  it may be relevant that both are of 
much  lower molecular  weight  than the  inhibitory  com- 
pounds. A requirement of high molecular weight for a sul- 
fated glycoconjugate to be inhibitory in vivo could result for 
various reasons, such as the relative absolute levels of high 
and lower molecular weight compounds required for inhibi- 
tion (not determined in this study) and their relative rates of 
dilution in or loss from the blood stream. Besides, in vivo 
inhibition may involve mechanisms in addition to those oper- 
ating in in vitro inhibition, such as the blocking of processes 
associated  with the movement of sporozoites  through the 
blood stream or their uptake by endothelial or Kupffer cells 
in the liver before the invasion of hepatocytes. 
A  further understanding  at  the  molecular  level  of the 
mechanisms leading to inhibition of sporozoite infectivity by 
sulfated glycoconjugates should provide information useful 
for understanding the molecular  and cellular basis  for the 
sporozoite invasion process. This will hopefully suggest ad- 
ditional approaches for limiting the initiation of plasmodial 
infections by targeting specific molecular processes  for the 
development of novel vaccines  and drugs. 
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